Stephan P Keijmel1,2, Corine E Delsing3, Gijs Bleijenberg4, Jos W M van der Meer1,2, Rogier T Donders5, Monique Leclercq6, Linda M Kampschreur7, Michel van den Berg8, Tom Sprong2,9, Marrigje H Nabuurs-Franssen10, Hans Knoop4,11, Chantal P Bleeker-Rovers1,2. 1. Radboud Expertise Center for Q Fever, Nijmegen, The Netherlands. 2. Department of Internal Medicine, Division of Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Internal Medicine, Medical Spectrum Twente, Enschede, The Netherlands. 4. Expert Centre for Chronic Fatigue, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 5. Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands. 6. Department of Internal Medicine, Bernhoven Hospital, Uden, The Netherlands. 7. Department of Internal Medicine, Medical Center Leeuwarden, The Netherlands. 8. Q-uestion, Foundation for Patients With Q Fever, Eindhoven, The Netherlands. 9. Department of Internal Medicine, Canisius-Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands. 10. Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. 11. Department of Medical Psychology, Academic Medical Center, University of Amsterdam, The Netherlands.
Abstract
Background: Approximately 20% of patients with acute Q fever will develop chronic fatigue, referred to as Q fever fatigue syndrome (QFS). The objective of this randomized controlled clinical trial was to assess the efficacy of either long-term treatment with doxycycline or cognitive-behavioral therapy (CBT) in reducing fatigue severity in patients with QFS. Methods:Adult patients were included who met the QFS criteria according to the Dutch guideline: a new onset of severe fatigue lasting ≥6 months with significant disabilities, related to an acute Q fever infection, without other somatic or psychiatric comorbidity explaining the fatigue. Using block randomization, patients were randomized between oral study medication and CBT (2:1) for 24 weeks. Second, a double-blind randomization between doxycycline (200 mg/day, once daily) and placebo was performed in the medication group. Primary outcome was fatigue severity at end of treatment (EOT; week 26), assessed with the Checklist Individual Strength subscale Fatigue Severity. Results: Of 155 patients randomized, 154 were included in the intention-to-treat analysis (doxycycline, 52; placebo, 52; CBT, 50). At EOT, fatigue severity was similar between doxycycline (40.8 [95% confidence interval {CI}, 37.3-44.3]) and placebo (37.8 [95% CI, 34.3-41.2]; difference, doxycycline vs placebo, -3.0 [97.5% CI, -8.7 to 2.6]; P = .45). Fatigue severity was significantly lower after CBT (31.6 [95% CI, 28.0-35.1]) than after placebo (difference, CBT vs placebo, 6.2 [97.5% CI, .5-11.9]; P = .03). Conclusions: CBT is effective in reducing fatigue severity in QFS patients. Long-term treatment with doxycycline does not reduce fatigue severity in QFS patients compared to placebo. Clinical Trials Registration: NCT01318356.
RCT Entities:
Background: Approximately 20% of patients with acute Q fever will develop chronic fatigue, referred to as Q fever fatigue syndrome (QFS). The objective of this randomized controlled clinical trial was to assess the efficacy of either long-term treatment with doxycycline or cognitive-behavioral therapy (CBT) in reducing fatigue severity in patients with QFS. Methods: Adult patients were included who met the QFS criteria according to the Dutch guideline: a new onset of severe fatigue lasting ≥6 months with significant disabilities, related to an acute Q fever infection, without other somatic or psychiatric comorbidity explaining the fatigue. Using block randomization, patients were randomized between oral study medication and CBT (2:1) for 24 weeks. Second, a double-blind randomization between doxycycline (200 mg/day, once daily) and placebo was performed in the medication group. Primary outcome was fatigue severity at end of treatment (EOT; week 26), assessed with the Checklist Individual Strength subscale Fatigue Severity. Results: Of 155 patients randomized, 154 were included in the intention-to-treat analysis (doxycycline, 52; placebo, 52; CBT, 50). At EOT, fatigue severity was similar between doxycycline (40.8 [95% confidence interval {CI}, 37.3-44.3]) and placebo (37.8 [95% CI, 34.3-41.2]; difference, doxycycline vs placebo, -3.0 [97.5% CI, -8.7 to 2.6]; P = .45). Fatigue severity was significantly lower after CBT (31.6 [95% CI, 28.0-35.1]) than after placebo (difference, CBT vs placebo, 6.2 [97.5% CI, .5-11.9]; P = .03). Conclusions: CBT is effective in reducing fatigue severity in QFS patients. Long-term treatment with doxycycline does not reduce fatigue severity in QFS patients compared to placebo. Clinical Trials Registration: NCT01318356.
Authors: Suzanne C Danhauer; Michael E Miller; Jasmin Divers; Andrea Anderson; Gena Hargis; Gretchen A Brenes Journal: Glob Adv Health Med Date: 2022-05-16
Authors: Wouter Schakel; Christina Bode; Hilde P A van der Aa; Carel T J Hulshof; Judith E Bosmans; Gerardus H M B van Rens; Ruth M A van Nispen Journal: BMJ Open Date: 2017-08-03 Impact factor: 2.692
Authors: Ruud P H Raijmakers; Anne F M Jansen; Stephan P Keijmel; Teske Schoffelen; Anja Scholzen; Jos W M van der Meer; Leo A B Joosten; Mihai G Netea; Marcel van Deuren; Chantal P Bleeker-Rovers Journal: Eur J Clin Microbiol Infect Dis Date: 2018-05-26 Impact factor: 3.267
Authors: Ruud P H Raijmakers; Anne F M Jansen; Stephan P Keijmel; Rob Ter Horst; Megan E Roerink; Boris Novakovic; Leo A B Joosten; Jos W M van der Meer; Mihai G Netea; Chantal P Bleeker-Rovers Journal: J Transl Med Date: 2019-05-14 Impact factor: 5.531
Authors: Ben Z Katz; Simon M Collin; Gabrielle Murphy; Rona Moss-Morris; Vegard Bruun Wyller; Knut-Arne Wensaas; Jeannine L A Hautvast; Chantal P Bleeker-Rovers; Ute Vollmer-Conna; Dedra Buchwald; Renée Taylor; Paul Little; Esther Crawley; Peter D White; Andrew Lloyd Journal: Fatigue Date: 2018-01-19